ArticlePloS one2009
The genetic requirements for fast and slow growth in mycobacteria.
Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 140 citations in OpenAlex.
- Mycobacterium tuberculosis VadK is required for the regulation of the methylcitrate cycle and virulence.EMBO reports · 2026Article
- Transcription attenuation amplifies collateral vulnerabilities in rifampicin-resistant Mycobacterium tuberculosis.Nature microbiology · 2026Article
- Review
- Immune Responsiveness Induced by Administration of Heat-Inactivated M. bovis and BCG Prior to Experimental Infection in African Buffalo.Transboundary and emerging diseases · 2026Article
- VadK, a Non-Canonical Kinase that Regulates the Methylcitrate Cycle and is Essential forbioRxiv : the preprint server for biology · 2025Article
- Characterization of Mycobacterium antarcticum sp. nov., a psychrotolerant member of the genus Mycobacterium isolated from Antarctic soil.Scientific reports · 2025Article
- Natural Products with Potent Antimycobacterial Activity (2000-2024): A Review.Molecules (Basel, Switzerland) · 2025Review
- TnSeq identifies genetic requirements of Mycobacterium tuberculosis for survival under vaccine-induced immunity.NPJ vaccines · 2025Article
- Article
- The spleen assumes a major role in blood glucose regulation in type 1 diabetes patients treated with BCG.Scientific reports · 2024Article
- Agent-based model predicts that layered structure and 3D movement work synergistically to reduce bacterial load in 3D in vitro models of tuberculosis granuloma.PLoS computational biology · 2024Article
- Structural and functional characterization of FabG4 from Mycolicibacterium smegmatis.Acta crystallographica. Section F, Structural biology communications · 2024Article
- The use of Kudoh method for culture of Mycobacterium tuberculosis and Mycobacterium africanum in The Gambia.PloS one · 2024Article
- In silico agent-based modeling approach to characterize multiple in vitro tuberculosis infection models.PloS one · 2024Article
- Metabolism and physiology of pathogenic bacterial obligate intracellular parasites.Frontiers in cellular and infection microbiology · 2024Review
- Dynamics of parasite growth in genetically diverse Plasmodium falciparum isolates.Molecular and biochemical parasitology · 2023Article
- A Review on Mycobacteriophages: From Classification to Applications.Pathogens (Basel, Switzerland) · 2022Review
- Bacterial growth dynamics and pharmacokinetic-pharmacodynamic relationships of rifampicin and bedaquiline in BALB/c mice.British journal of pharmacology · 2022Article
- Article
- Modulatory Impact of the sRNA Mcr11 in Two Clinical Isolates of Mycobacterium tuberculosis.Current microbiology · 2022Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Mycobacterium tuberculosis infects a third of the world's population. Primary tuberculosis involving active fast bacterial replication is often followed by asymptomatic latent tuberculosis, which is characterised by slow or non-replicating bacteria. Reactivation of the latent infection involving a switch back to active bacterial replication can lead to post-primary transmissible tuberculosis. Mycobacterial mechanisms involved in slow growth or switching growth rate provide rational targets for the development of new drugs against persistent mycobacterial infection. Using chemostat culture to control growth rate, we screened a transposon mutant library by Transposon site hybridization (TraSH) selection to define the genetic requirements for slow and fast growth of Mycobacterium bovis (BCG) and for the requirements of switching growth rate. We identified 84 genes that are exclusively required for slow growth (69 hours doubling time) and 256 genes required for switching from slow to fast growth. To validate these findings we performed experiments using individual M. tuberculosis and M. bovis BCG knock out mutants. We have demonstrated that growth rate control is a carefully orchestrated process which requires a distinct set of genes encoding several virulence determinants, gene regulators, and metabolic enzymes. The mce1 locus appears to be a component of the switch to slow growth rate, which is consistent with the proposed role in virulence of M. tuberculosis. These results suggest novel perspectives for unravelling the mechanisms involved in the switch between acute and persistent TB infections and provide a means to study aspects of this important phenomenon in vitro.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.